Abstract
This article presents the results of a retrospective study of the prevalence of nontoxigenic and toxigenic C. difficile strains in hematological oncology patients. The detection rate of C. difficile in hematological oncology patients was 22,5%, of which toxigenic strains accounted for 38,5%. Toxigenic C. difficile strains were most often detected in patients with acute leukemia (46,7%). More than half of the detected toxigenic C. difficile strains (53,3%) were found in patients over 65 years of age. Among patients in whom toxigenic strains of C. difficile were detected, men accounted for 46.7%, women – 53,3%. 64,1% of patients had a history of multiple hospitalizations (from 2 to 15). The median length of hospitalization was 30,5 [18,5; 41,5] bed-days. Combination antibacterial therapy (two or more antibiotics) was used in 79,5% of patients, chemotherapy in 71,8%, and proton pump inhibitor therapy in 69,2%. Secondary immunodeficiency was diagnosed in 87,2% of patients with oncohematological diseases.